; (iv) determine a fair price for each applicable drug, in accordance with subparagraph (B); (v) sell manufactured applicable drugs at a fair price as authorized under this section; and (vi) manufacture, or enter into contracts with entities, with preference for nonprofit entities and public partners, to manufacture active pharmaceutical ingredients for use by the Office or for sale to other entities. (B) Transparency All prices paid and charged for applicable drugs and their inputs shall be made publicly available by the Office. (C) Fair price In determining a fair price (the price at which the Office sells an applicable drug to a wholesaler or direct purchaser) for an applicable drug under subparagraph (A)(iv) the Office shall consider— (i) the impact of price on patient access to the applicable drug; (ii) the cost of the applicable drug to Federal or State health care programs; (iii) the cost to the Federal Government of manufacturing the applicable drug; (iv) the administrative costs of operating the Office; (v) the cost to acquire or manufacture applicable drugs under this section; (vi) the impact of price on market competition for the applicable drug; (vii) the impact of formulary design on patient access to the applicable drug; and (viii) the cost to acquire the applicable drug at the National Average Drug Acquisition Cost. (D) Acquiring right to manufacture and market The Office may acquire the rights to manufacture and market applicable drugs as authorized under this section. (E) Active pharmaceutical ingredients (i) In general The Office shall manufacture, or enter into contracts with entities to manufacture, an active pharmaceutical ingredient if— (I) the Office determines that such ingredient is not readily available from existing suppliers; (II) such ingredient is supplied by a single manufacturing facility; (III) such ingredient is necessary for the manufacture of medical countermeasures or medicines deemed essential from a public health perspective